Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 13270.0
(-0.6%)
KRW 13270.0
(-0.6%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 84.96 Billion KRW | 68.75% |
| 2022 | 50.35 Billion KRW | 24.77% |
| 2021 | 40.35 Billion KRW | -18.15% |
| 2020 | 49.3 Billion KRW | 52.06% |
| 2019 | 32.42 Billion KRW | -14.4% |
| 2018 | 37.87 Billion KRW | -38.72% |
| 2017 | 61.81 Billion KRW | 8.53% |
| 2016 | 56.95 Billion KRW | 116.2% |
| 2015 | 26.34 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 85.17 Billion KRW | 0.24% |
| 2024 Q2 | 73.92 Billion KRW | -13.21% |
| 2023 Q1 | 58.51 Billion KRW | 16.22% |
| 2023 FY | 84.96 Billion KRW | 68.75% |
| 2023 Q4 | 84.96 Billion KRW | 2.86% |
| 2023 Q3 | 82.6 Billion KRW | 12.7% |
| 2023 Q2 | 73.29 Billion KRW | 25.26% |
| 2022 FY | 50.35 Billion KRW | 24.77% |
| 2022 Q2 | 39.65 Billion KRW | 3.34% |
| 2022 Q1 | 38.37 Billion KRW | -4.9% |
| 2022 Q4 | 50.35 Billion KRW | -4.19% |
| 2022 Q3 | 52.55 Billion KRW | 32.51% |
| 2021 FY | 40.35 Billion KRW | -18.15% |
| 2021 Q2 | 39.58 Billion KRW | -14.02% |
| 2021 Q1 | 46.03 Billion KRW | -6.62% |
| 2021 Q3 | 40.53 Billion KRW | 2.4% |
| 2021 Q4 | 40.35 Billion KRW | -0.44% |
| 2020 FY | 49.3 Billion KRW | 52.06% |
| 2020 Q1 | 30.54 Billion KRW | -5.79% |
| 2020 Q4 | 49.3 Billion KRW | -2.97% |
| 2020 Q3 | 50.81 Billion KRW | 16.12% |
| 2020 Q2 | 43.75 Billion KRW | 43.24% |
| 2019 Q1 | 36.36 Billion KRW | -4.0% |
| 2019 Q4 | 32.42 Billion KRW | -2.98% |
| 2019 FY | 32.42 Billion KRW | -14.4% |
| 2019 Q3 | 33.41 Billion KRW | -7.71% |
| 2019 Q2 | 36.21 Billion KRW | -0.42% |
| 2018 FY | 37.87 Billion KRW | -38.72% |
| 2018 Q4 | 37.87 Billion KRW | -17.13% |
| 2018 Q3 | 45.7 Billion KRW | -7.42% |
| 2018 Q2 | 49.37 Billion KRW | -11.45% |
| 2018 Q1 | 55.75 Billion KRW | -9.8% |
| 2017 Q3 | 63.93 Billion KRW | 40.11% |
| 2017 Q4 | 61.81 Billion KRW | -3.32% |
| 2017 FY | 61.81 Billion KRW | 8.53% |
| 2017 Q2 | 45.63 Billion KRW | 0.0% |
| 2016 FY | 56.95 Billion KRW | 116.2% |
| 2015 FY | 26.34 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -27.038% |
| Yuhan Corporation | 230.07 Billion KRW | 63.07% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -115.61% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 77.761% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 87.72% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 50.103% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 50.103% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 81.846% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -96.349% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 50.896% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -177.103% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 53.057% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 41.824% |
| Boryung Corporation | 204.21 Billion KRW | 58.394% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 0.228% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 63.943% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -6483.778% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -13343.384% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 6.097% |
| CKD Bio Corp. | 146.92 Billion KRW | 42.171% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 62.247% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 61.338% |
| Yuhan Corporation | 230.07 Billion KRW | 63.07% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -84.102% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -115.61% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -220.225% |
| HANDOK Inc. | 300.01 Billion KRW | 71.679% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 79.109% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 85.168% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -14168.287% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 81.839% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 28.383% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -115.61% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -35580.949% |
| JW Holdings Corporation | 554.58 Billion KRW | 84.679% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 60.997% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 50.103% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -116.722% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 51.691% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 81.91% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -84.102% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -110.629% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -76.075% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -7.027% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 0.228% |
| JW Lifescience Corporation | 46.31 Billion KRW | -83.46% |